Ivermectin plasma concentration in Iberian Ibex (Capra pyrenaica) following oral administration: a pilot study

dc.contributor.authorMoroni, Barbara
dc.contributor.authorGranados Torres, José Enrique
dc.contributor.authorLópez-Olvera, Jorge Ramón
dc.contributor.authorEspinosa Cerrato, José
dc.contributor.authorRáez-Bravo, Arián
dc.contributor.authorMentaberre García, Gregorio
dc.contributor.authorFandos, Paulino
dc.contributor.authorPazzi, Marco
dc.contributor.authorRomagnoli, Monica
dc.contributor.authorGardini, Giulia
dc.contributor.authorRossi, Luca
dc.contributor.authorValldeperes, Marta
dc.date.accessioned2022-05-20T08:56:11Z
dc.date.available2022-05-20T08:56:11Z
dc.date.issued2022
dc.description.abstractSarcoptic mange is considered the main driver of demographic declines occurred in the last decades in Iberian ibex (Capra pyrenaica) populations. Mass treatment campaigns by administration of in-feed acaricides are used as a measure to mitigate the impact of mange in the affected populations. However, there are no data on ivermectin (IVM) pharmacokinetics in this wild caprine, and the treatment through medicated feed is not endorsed by evidence on its effectiveness. The aim of this study is to determine the pharmacokinetic profile of IVM in plasma samples of ibexes after the experimental oral administration of IVM, using high performance liquid chromatography (HPLC) with automated solid phase extraction and fluorescence detection. A dose of 500 μg of IVM per body weight was orally administered in a feed bolus to nine healthy adult ibexes (seven males and two females). Blood samples were collected by jugular venipuncture into heparin-coated tubes at day 1, 2, 3, 4, 7, 10, 15, and 45 post-administration (dpa). The highest plasma concentration of IVM (Cmax = 3.4 ng/ml) was detected 24 h after the oral administration (T1), followed by a rapid decrease during the first week post-administration. Our results reveal that plasma IVM concentration drops drastically within 5 days of ingestion, questioning the effectiveness of a single in-feed dose of this drug to control sarcoptic mange. To the best of our knowledge, this is the first study on plasma availability of oral IVM in ibexes and in any wild ungulate species.ca_ES
dc.description.sponsorshipThis project was funded by the Consejería de Medio Ambiente de la Junta de Andalucía (project 173/2009/M/00; 03/15/M/00; 861_11_M_00 and 2016/00014/M), and by the Spanish Ministerio de Economía y Competitividad (projects CGL2012-40043-C02-01, CGL2012-40043-C02-02, and CGL2016-80543-P). The authors' research activities are partially supported by the Plan Andaluz de Investigación (RNM-118 group). MV is supported by a FI-GENCAT Fellowship (2020_FI_B2_00049, co-financiated by Agència de Gestió d'Ajuts Universitaris i de Recerca and European Social Fund) and ES by the Spanish Ministerio de Ciencia Innovación y Universidades (MICINN) through a Ramon y Cajal agreement (RYC-2016-21120). GM is a Serra Húnter Fellow.ca_ES
dc.identifier.doihttps://doi.org/10.3389/fvets.2022.830157
dc.identifier.issn2297-1769
dc.identifier.urihttp://hdl.handle.net/10459.1/83331
dc.language.isoengca_ES
dc.publisherFrontiers Media S.A.ca_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO//CGL2012-40043-C02-01/ES/EPIDEMIOLOGIA, INMUNOLOGIA Y PATOLOGIA DE LA SARNA SARCOPTICA EN LA CABRA MONTES/ca_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO//CGL2012-40043-C02-02/ES/CARACTERIZACION DE LA INFESTACION EXPERIMENTAL POR SARCOPTES SCABIEI EN LA CABRA MONTES (CAPRA PYRENAICA)/ca_ES
dc.relationinfo:eu-repo/grantAgreement/AEI//CGL2016-80543-P/ES/ca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.3389/fvets.2022.830157ca_ES
dc.relation.ispartofFrontiers in veterinary science, 2022, vol. 91, núm. 830157, p. 1-7ca_ES
dc.rightscc-by (c) Moroni et al., 2022ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectIberian ibexca_ES
dc.subjectIvermectinca_ES
dc.subjectMedicated feedca_ES
dc.subjectSarcoptic mangeca_ES
dc.subjectTreatmentca_ES
dc.subjectWildlifeca_ES
dc.subject.otherMalalties parasitàriesca_ES
dc.subject.otherSarna --Tractamentca_ES
dc.subject.otherMedicaments--Modes d'administracióca_ES
dc.subject.otherAnimals--Alimentacióca_ES
dc.titleIvermectin plasma concentration in Iberian Ibex (Capra pyrenaica) following oral administration: a pilot studyca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
frovetsci_a2022v91n830157p1.pdf
Size:
375.82 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: